This research was developed with funding from the Defense Advanced Research Projects Agency (DARPA). The views, opinions and/or findings expressed are those of the author(s) and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government." (Approved for Public Release. Distribution Unlimited 12/8/20)

Clinical-grade, self-sampling, at-home blood collection

The in-person blood draw has been the standard of care for more than 60 years. Today’s surging demand for telemedicine highlights the shortcomings of a painful, inconvenient, and inconsistent test procedure that requires trained phlebotomists.

Tasso is transforming the traditional diagnostic standard of care with a clinical-grade, convenient and virtually painless blood collection experience. The Tasso OnDemand devices enable people to collect their own blood with the push of a button from the comfort of their home. The devices require no training and offer large capillary blood volumes, multiple preparation options, and seamless integration with standard analyzers. The kit easily ships via standard post or specialized couriers. Tasso offers logistics services to help ensure the samples are collected from the right patients and sent to the qualified laboratories for analysis.

IMPACT

An easy-to-use, self-sampling device enables more individuals to benefit from the latest advances in diagnostic blood testing and virtual patient care. The Tasso OnDemand devices are currently being validated for a wide variety of applications, including routine diagnostics, chronic disease monitoring, infectious disease surveillance, athletic and sports testing, virtual clinical trials, global health, and healthcare for under-served populations.

BEYOND PHASE II

Tasso received an NIH grant, additional DARPA funding of $2.9M to develop advancements for stabilization and shipping of blood, and funding from DTRA to develop a reliable, safe, and simple universal surveillance platform for infectious disease outbreak. Tasso made its first sale to Merck & Co, Inc. The company recently secured a $17 M Series A venture funding round to scale production. Tasso continues to pursue strategic partnerships and licensing agreements.